Data / Drug companies / Somatostatin Analog
Somatostatin Analog drugs: 4 drugs from 17 companies in the FDA NDC directory
Somatostatin Analog is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 51 products in this class from 17 companies, covering 4 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on September 23, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 17Companies
- 51Products
- 4Drugs by generic name
Drugs in the Somatostatin Analog class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Octreotide acetate | 33 | 11 |
| Lanreotide acetate | 13 | 4 |
| Octreotide | 2 | 2 |
| Pasireotide | 3 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Cipla USA Inc. | 6 | injection | New drug applications (NDA) | May 30, 2025 |
| Fresenius Kabi USA, LLC | 6 | injection, solution | Generic drugs (ANDA) | March 14, 2006 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 5 | injection, solution | Generic drugs (ANDA) | May 25, 2022 |
| Hikma Pharmaceuticals USA Inc. | 5 | injection, solution | Generic drugs (ANDA) | April 8, 2005 |
| Gland Pharma Limited | 4 | injection, solution | Generic drugs (ANDA) | June 22, 2023 |
| Exelan Pharmaceuticals Inc. | 3 | injection | Generic drugs (ANDA) | May 30, 2025 |
| Ipsen Biopharmaceuticals, Inc. | 3 | injection | New drug applications (NDA) | November 14, 2007 |
| Meitheal Pharmaceuticals Inc. | 3 | injection, solution | Generic drugs (ANDA) | February 28, 2025 |
| Mylan Institutional LLC | 3 | injection, solution | Generic drugs (ANDA) | April 1, 2011 |
| Novartis Pharmaceuticals Corporation | 3 | injection, solution | New drug applications (NDA) | October 21, 1988 |
| Recordati Rare Diseases, Inc. | 3 | injection | New drug applications (NDA) | December 14, 2012 |
| Glenmark Pharmaceuticals Inc., USA | 2 | injection, solution | Generic drugs (ANDA) | August 9, 2023 |
| Amneal Pharmaceuticals LLC | 1 | injection | Generic drugs (ANDA) | September 23, 2026 |
| Amryt Pharmaceuticals Designated Activity Company | 1 | capsule, delayed release | New drug applications (NDA) | July 6, 2020 |
| Chiesi USA, Inc. | 1 | capsule, delayed release | New drug applications (NDA) | July 6, 2020 |
| Hainan Shuangcheng Pharmaceuticals Co., Ltd. | 1 | injection, solution | Generic drugs (ANDA) | May 2, 2024 |
| Sun Pharmaceutical Industries, Inc. | 1 | injection | New drug applications (NDA) | February 24, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 32 | 62.7% |
| Injection | 17 | 33.3% |
| Capsule, delayed release | 2 | 3.9% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.